Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Needham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $42
Needham analyst Serge Belanger maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and lowers the price target from $48 to $42.
KalVista Pharmaceuticals Announces Initiation Of KVD900 Phase 3 KONFIDENT Clinical Trial
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Needham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $48
Needham analyst Serge Belanger maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and lowers the price target from $50 to $48.
KalVista Pharmaceuticals: Q2 Earnings Insights
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.